Bovine Lactoferrin Enhances the Efficacy of Levofloxacin-based Triple Therapy As First-line Treatment of Helicobacter Pylori Infection: an in Vitro and in Vivo Study

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Jan 23

PMID 30668729

Citations 17

Authors

Antonio Francesco Ciccaglione

Mara Di Giulio

Silvia Di Lodovico

Emanuela Di Campli

Luigina Cellini

Leonardo Marzio

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection.

Methods: The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [13C]urea breath test.

Results: In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10 mg/mL and expressed 50% bactericidal effect at 40 mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%-92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%-101.38%).

Conclusions: Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect.

Citing Articles

: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.

Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.

PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.

infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review.

Liu M, Gao H, Miao J, Zhang Z, Zheng L, Li F Front Microbiol. 2024; 14:1330029.

PMID: 38268702 PMC: 10806011. DOI: 10.3389/fmicb.2023.1330029.

Lactoferrin-The Health-Promoting Properties and Contemporary Application with Genetic Aspects.

Janczuk A, Brodziak A, Czernecki T, Krol J Foods. 2023; 12(1).

PMID: 36613286 PMC: 9818722. DOI: 10.3390/foods12010070.

Antimicrobial activity of bovine lactoferrin against species clinical isolates.

Pino A, Mazza T, Matthews M, Castellana S, Caggia C, Randazzo C Front Microbiol. 2022; 13:1000822.

PMID: 36419418 PMC: 9678186. DOI: 10.3389/fmicb.2022.1000822.

Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update - III - Cow's milk allergens and mechanisms triggering immune activation.

Jensen S, Fiocchi A, Baars T, Jordakieva G, Nowak-Wegrzyn A, Pali-Scholl I World Allergy Organ J. 2022; 15(9):100668.

PMID: 36185551 PMC: 9483786. DOI: 10.1016/j.waojou.2022.100668.

References

Wada T, Aiba Y, Shimizu K, Takagi A, Miwa T, Koga Y . The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol. 1999; 34(3):238-43. DOI: 10.1080/00365529950173627. View

Calvet X, Cubells M, Bare M, Galvez E, Molina E . Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther. 1999; 13(6):781-6. DOI: 10.1046/j.1365-2036.1999.00552.x. View

Huang J, Hunt R . Treatment after failure: the problem of "non-responders". Gut. 1999; 45 Suppl 1:I40-4. PMC: 1766657. DOI: 10.1136/gut.45.2008.i40. View

Dial E, Romero J, Headon D, Lichtenberger L . Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol. 2001; 52(12):1541-6. DOI: 10.1211/0022357001777595. View

Singh P, Parsek M, Greenberg E, Welsh M . A component of innate immunity prevents bacterial biofilm development. Nature. 2002; 417(6888):552-5. DOI: 10.1038/417552a. View

Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T . The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002; 7(5):306-9. DOI: 10.1046/j.1523-5378.2002.00096.x. View

Guttner Y, Windsor H, Viiala C, Marshall B . Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther. 2002; 17(1):125-9. DOI: 10.1046/j.1365-2036.2003.01395.x. View

Odds F . Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003; 52(1):1. DOI: 10.1093/jac/dkg301. View

Borody T, Ashman O . Lactoferrin: milking ulcers?. Dig Liver Dis. 2003; 35(10):691-3. DOI: 10.1016/s1590-8658(03)00412-2. View

10.

Di Mario F, Aragona G, Dal Bo N, Cavestro G, Cavallaro L, Iori V . Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis. 2003; 35(10):706-10. DOI: 10.1016/s1590-8658(03)00409-2. View

11.

Megraud F . H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9):1374-84. PMC: 1774187. DOI: 10.1136/gut.2003.022111. View

12.

Sanchez L, Calvo M, Brock J . Biological role of lactoferrin. Arch Dis Child. 1992; 67(5):657-61. PMC: 1793702. DOI: 10.1136/adc.67.5.657. View

13.

Iacopini F, Crispino P, Paoluzi O, Consolazio A, Pica R, Rivera M . One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis. 2005; 37(8):571-6. DOI: 10.1016/j.dld.2005.03.007. View

14.

Okuda M, Nakazawa T, Yamauchi K, Miyashiro E, Koizumi R, Booka M . Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study. J Infect Chemother. 2005; 11(6):265-9. DOI: 10.1007/s10156-005-0407-x. View

15.

Cellini L, Grande R, Di Campli E, Di Bartolomeo S, Capodicasa S, Marzio L . Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol. 2006; 41(3):280-7. DOI: 10.1080/00365520510024223. View

16.

Nista E, Candelli M, Zocco M, Cremonini F, Ojetti V, Finizio R . Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol. 2006; 101(9):1985-90. DOI: 10.1111/j.1572-0241.2006.00716.x. View

17.

De Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F . Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007; 102(5):951-6. DOI: 10.1111/j.1572-0241.2007.01085.x. View

18.

Roncarati D, Danielli A, Spohn G, Delany I, Scarlato V . Transcriptional regulation of stress response and motility functions in Helicobacter pylori is mediated by HspR and HrcA. J Bacteriol. 2007; 189(20):7234-43. PMC: 2168435. DOI: 10.1128/JB.00626-07. View

19.

Jenssen H, Hancock R . Antimicrobial properties of lactoferrin. Biochimie. 2008; 91(1):19-29. DOI: 10.1016/j.biochi.2008.05.015. View

20.

Gisbert J . "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008; 14(35):5385-402. PMC: 2744171. DOI: 10.3748/wjg.14.5385. View